Introduction
============

Micro-ribonucleic acids (miRNAs) are a class of small noncoding RNAs that regulate gene expression at the post-transcriptional level and play an important regulatory role in many cellular processes.^[@b1-1020746]^ Deregulated expression of miRNAs could play a critical oncogenic or tumor-suppressor role and has therefore been associated with cancer, including hematological malignancies and, especially, B-cell lymphomas.^[@b2-1020746]--[@b4-1020746]^ MiRNAs correlate with the clinical characteristics or outcome of chronic lymphocytic leukemia (CLL) patients, allowing the identification of CLL subgroups with worse outcomes.^[@b5-1020746]--[@b7-1020746]^ Some of these miRNAs contribute to the deregulation of pathways involved in CLL oncogenic processes, such as PI3K/Akt (miR-22), NF-κB (miR-9 family), or toll-like receptor 9 (miR-17\~92 family).^[@b8-1020746]--[@b10-1020746]^ The B-cell receptor (BCR) signaling pathway was recently shown to be directly regulated by miR-34, miR-150, and miR-155 in CLL,^[@b11-1020746],[@b12-1020746]^ in addition to BCL2 (miR-15a/16), TCL1 (miR-29 and miR-181), P53 (miR-15a/miR-16-1 cluster, miR-17-5p, miR-29c and miR-34a), or PTEN (miR-26a and miR-214).^[@b13-1020746]--[@b17-1020746]^ Response to a CLL treatment could also be regulated by miRNAs. Thus, patients refractory to fludarabine exhibit significantly higher expression levels of miR-21, miR-148a and miR-222 than fludarabine sensitive patients.^[@b18-1020746]^ The activation of P53-responsive genes was found only in fludarabine responsive patients, suggesting a possible link between abnormal miRNA expression and P53 pathway dysfunction in non-responder patients. Links between miRNAs, fludarabine-refractory CLL and genomic abnormalities were further demonstrated, underlying the crucial role of *MYC* and *P53* regulatory networks in determining cell response to fludarabine in CLL.^[@b19-1020746]^ Finally, in a prospective clinical trial aiming at evaluating the contribution of 17p deletion or *TP53* mutation in fludarabine-refractory CLL, miR-34a expression at baseline was lower than in a control cohort of CLL non-refractory patients.^[@b20-1020746]^ The detection of miRNAs in serum and other body fluids under physiological and pathological conditions raises the possibility of using them as diagnostic or prognostic biomarkers.^[@b21-1020746]--[@b23-1020746]^ Visone *et al.* found that blood expression levels of miR-181b decreased in progressive CLL patients but not in patients with stable disease.^[@b24-1020746]^ Recently, we have shown that high miR-125b blood concentration can predict clinical benefit of rituximab (MabThera®, Rituxan®) treatment in patients with rheumatoid arthritis, and preliminary results suggested a similar prognostic value of miR-125b in B-cell lymphoma patients.^[@b25-1020746]^ Interestingly, the expression of miR-125b is high in hematopoietic stem cells (HSCs) and decreases in committed progenitors.^[@b26-1020746]^ In addition, overexpression of miR-125b in mice HSCs is associated with the development of lymphoproliferative disease.^[@b27-1020746]^ Finally, miR-125b expression is reduced in CLL patients as compared with healthy donors.^[@b28-1020746]^ Altogether, these studies suggest that low expression of circulating miR-125b might be associated with lymphoproliferation and poor treatment response to rituximab.

The *in vivo* mechanisms of rituximab action remain incompletely understood, and could differ depending on the subtype of B-lymphoproliferative disorders. *In vitro* data demonstrate that rituximab is able to induce apoptosis, complement-dependent cytotoxicity (CDC), antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP). Although the influence of FcγRIIIa-V158VV on rituximab response in follicular lymphoma patients strongly suggests that ADCC occurs *in vivo*, there is a lack of evidence for the other immune mechanisms.^[@b29-1020746]^ One of the main barriers to improve our knowledge is the scarcity of clinical situations in which rituximab is used alone. Indeed, chemotherapy associated with rituximab pollutes any definitive conclusions in studies attempting to analyze *in vivo* rituximab mechanisms of action. Recently, we conducted a clinical phase II study testing a new approach of dose-dense rituximab pre-phase before immunochemotherapy.^[@b30-1020746]^ This study was based on increased rituximab elimination observed in CLL patients compared to lymphoma patients in different clinical trials.^[@b31-1020746]^ Thus, this study provided a unique opportunity to dissect the mechanisms of action of rituximab in CLL patients. The study herein aimed at identifying a blood-based miRNA signature at diagnosis, before rituximab monotherapy, that predicts rituximab efficacy in CLL patients. It also aimed at shedding light on the miRNA-mediated molecular mechanisms involved in rituximab's mode of action *in vivo*.

Methods
=======

CLL2010FMP protocol
-------------------

A prospective, randomized, open-label, phase II study (CLL2010FMP, *[clinicaltrials.gov](http://clinicaltrials.gov) Identifier: 01370772*) included 140 treatment-naive patients (aged 18--65 years) diagnosed with confirmed chronic lymphocytic leukemia, according to the International Workshop on Chronic Lymphocytic Leukemia (IWCLL) 2008 criteria, and Binet stage C, or with active Binet stage A or B.^[@b32-1020746]^ An additional inclusion criteria was the absence of 17p deletion, assessed by fluorescence *in situ* hybridization (FISH) (\<10% positive nuclei). Each patient provided written informed consent before enrolment. Participating centers are listed in the *Online Supplementary Information*. Patients were stratified according to *IGHV* mutational status, FISH analysis (11q deletion or not) and were randomly assigned to receive either 6 cycles of chemoimmunotherapy combining fludarabine, cyclophosphamide, and rituximab (FCR) (rituximab 375mg/m^2^ for the first course, Day (D)1 and 500mg/m^2^ for the others, fludarabine 40mg/m^2^/d D2--4, cyclophosphamide 250mg/m^2^/d D2-4) every 28 days, or Dense-FCR with an intensified rituximab pre-phase (500mg on D0, and 2000mg on D1, D8 and D15) before initiating the standard FCR treatment. The main objective was to increase the complete response rate with undetectable minimal residual disease three months after treatment, as published previously.^[@b30-1020746]^ In the study herein we have explored miRNA signature in a cohort of 123 patients, 61 receiving rituximab pre-phase before immunochemotherapy (Dense-FCR arm) and 62 receiving the FCR chemotherapy (standard arm). The study was approved by the institutional ethics committee of each participating center according to the principles of the Declaration of Helsinki.

Gene expression analysis
------------------------

Details are described in the Online Supplementary Information.

*FCGR3A* genotyping
-------------------

Single-step multiplex allele-specific PCR assays were performed as initially described by Dall'Ozzo *et al.* introducing minor modifications (for details see the *Online Supplementary Information*).

IL-10 competent CLL cells identification
----------------------------------------

Interleukin (IL)-10-competent CLL cell counts were determined by flow cytometry analysis of IL-10 production. Peripheral blood mononuclear cells (PBMCs) were purified from peripheral blood samples of the Dense-FCR arm of the protocol using Ficoll-Hypaque density gradients (Eurobio, Courtaboeuf, France).^[@b33-1020746]^ Clonal CLL cells were identified as CD19^+^ CD5^+^ CD20^int^ lymphocytes with a previously described protocol.^[@b34-1020746]^ Analyses were performed on a CyAnTM ADP flow cytometer (Beckman Coulter, Brea, CA, USA).

Cell surface CD20 expression analysis
-------------------------------------

CD20 expression was quantified using CD20-PE QuantiBRITE™ reagents (Ratio 1:1) according to manufacturer's recommendations (BD Biosciences, Le Pont-de-Claix, France). Calibration and quantification were performed using a FAC-SCANTO II cytometer (BD, Biosciences, Le Pont-de-Claix, France), and details are in the *Online Supplementary Information*. Circulating CD20 antigen was evaluated by considering the lymphocyte count and blood volume for each patient.

Statistical analysis
--------------------

The distribution of data was tested with the Shapiro-Wilk test. A X^2^ or Fisher's test were used to compare categorical data. For numerical data, medians were compared using a Student's *t*-test or Mann-Whitney test. All variables with a *P* value \<0.10 in univariate analysis were included in an intermediate model. The final model variables were determined by backward selection using a Student's *t*-test (*P*\<0.05 as significant model). The Spearman's correlation test was used to assess the association between two numerical data. All statistical analyses were performed at the conventional two-tailed α level of 0.05 using R software version 3.0.2.10.

Results
=======

Patients' characteristics
-------------------------

Sixty-one CLL patients were allocated to receive rituximab pre-phase. Their clinical and biological characteristics are presented in [Table 1](#t1-1020746){ref-type="table"}. They did not differ from the entire cohort. Median age was 58 years (interquartile range (IQR): 53--61), 28% were females and 77% were Binet stage A or B. Cytogenetic analysis demonstrated del11q in 20% of patients and median lymphocyte count was 89 G/L (IQR: 43--123).

###### 

Patients' characteristics for the protocol CLL2010FMP.

![](102746.tab1)

Blood miRNA expression profile discriminates CLL patients with high and low lymphocytosis
-----------------------------------------------------------------------------------------

Because miR-125b expression is reduced in CLL patients compared with healthy donors and is a key regulator of lymphoproliferation,^[@b28-1020746]^ we performed real-time PCR-based high-throughput miRNA arrays comparing CLL patients with high lymphocyte counts (\>93.93G/L, Q3) *versus* low lymphocyte counts (\<11.67G/L, Q1) at baseline. Q1 and Q3 were interquartile values of lymphocyte counts at D0 for patients of the Dense-FCR arm analyzed by TaqMan low-density array (TLDA). After filtering (fold change ≥1.5 and cycle threshold (Ct) values \<32) on the differentially expressed miRNAs, we found 5 miRNAs downregulated and 21 miRNAs upregulated in CLL patients with low lymphocyte counts compared with those with high lymphocyte counts (*P*\<0.05) ([Table 2](#t2-1020746){ref-type="table"}). The heat map showed results of the unsupervised hierarchical clustering based on the significantly differentially expressed miRNAs ([Figure 1A](#f1-1020746){ref-type="fig"}). Two patterns of miRNA expression profile named cluster 1 and cluster 2 were clearly identified according to lymphocyte counts. To confirm this finding, we selected four miRNAs (two from each cluster) based on technical criteria (21\<Ct\<29 and 2-fold difference between high and low lymphocyte count at D0 between two miRNAs in each cluster), and on the literature.^[@b28-1020746],[@b35-1020746],[@b36-1020746]^ We therefore assessed their expression in a cohort of 123 CLL patients ([Figure 1B](#f1-1020746){ref-type="fig"}). Expression patterns of miR-193b, miR-125b, miR-652 and miR-532-3p were consistent with the array data. Scatter plots confirmed that increased lymphocyte counts were inversely correlated with the expression levels of miR-193b and miR-125b (*P*=0.03 and *P*=0.0001, respectively) for cluster 1, and miR-652 and miR-532-3p (*P*=0.0017 and *P*=0.0001, respectively) for cluster 2 ([Figure 1B](#f1-1020746){ref-type="fig"}). No significant correlation was found between individual miRNAs (miR-125b, miR-193b, miR-532-3p, miR-652) and clinical (age, Binet stage, Eastern Cooperative Oncology Group (ECOG)) or biological (*IGHV* mutation, cytogenetic abnormalities (del11q, del13q, trisomy 12), B10 frequency, or FcγRIIIa-158V/F polymorphism) parameters (*data not shown*). Finally, our results demonstrated that all 4 miRNAs were markedly downregulated in the blood of CLL patients displaying high lymphocyte counts.

###### 

List of the 26 miRNAs differentially expressed in CLL patients with low or high lymphocyte counts at D0.

![](102746.tab2)

![MicroRNAs expression profile discriminates CLL patients with low or high lymphocyte counts before treatment. (A) The profiles of 26 microRNAs significantly differently expressed (*P*\<0.05) between high and low lymphocyte concentration samples isolated from CLL patients (n=5/group) were visualized using a supervised heatmap (average linkage and Pearson's correlation). Relative miRNA expression was calculated using the comparative threshold cycle (Ct) method. For normalization, the mean Ct value of all miRNA targets was used. Dendrograms indicated the correlation between groups of samples and miRNAs. Samples are in columns and miRNAs in rows. Each column represents an individual sample and each row represents a single miRNA. The heat map shows relative levels of miRNA expression in a green (low relative expression) to red (high relative expression) scale. (B--C) Expression levels of 4 miRNAs representative of each cluster, miR-193 band miR-125b for cluster 1 (B), and miR-532-3p and miR-652 for cluster 2 (C), were measured for 123 CLL patients included in the CLL2010FMP protocol, using RT-qPCR. A significant inverse correlation was observed depending on the lymphocyte counts for miR-193b r=−0.19), miR-125b (r=−0.39), miR-652 (r=−0.30) and miR-532-3p (r=−0.34) (Spearman's correlation test).](102746.fig1){#f1-1020746}

miR-125b and miR-532-3p expression levels correlate with lymphodepletion observed after rituximab treatment
-----------------------------------------------------------------------------------------------------------

We hypothesized that lymphocyte depletion observed after rituximab infusions was related to *in vivo* rituximab activity, and then monitored the lymphocyte depletion in our CLL cohort following four rituximab infusions at D22. We thus determined whether a correlation existed between the miRNA expression profile that discriminates CLL patients with high lymphocytosis before treatment and the efficacy of lymphocyte depletion with rituximab. The median lymphocyte count was 89G/L (range: 4--351) before rituximab treatment and 3G/L (range: 0.1--189) after four rituximab infusions, bringing the median lymphocyte depletion after rituximab treatment up to 95.9% (range: −5.0--99.6).

Only 2 out of the 4 validated miRNAs, namely miR-125b and miR-532-3p, were significantly correlated with lymphodepletion, whereas miR-652 and miR-193b did not correlate with lymphodepletion. Thus, the lymphodepletion rate was inversely correlated with the expression levels of miR-125b and miR-532-3p (*P*=0.020 and *P*=0.001, respectively), as shown in the scatter plots in [Figure 2](#f2-1020746){ref-type="fig"}. However, no correlation was found between miRNAs and the clinical response assessed 3 months after immunochemotherapy by FCR.

![Efficacy of lymphodepletion after rituximab treatment inversely correlates with miR-125b and miR-532-3p expression levels. miR-125b (r=−0.42) (A) and miR-532-3p (r=−0.49) (B) expression levels were quantified by RT-qPCR. The lymphodepletion was measured 22 days after 4 doses of rituximab infusion and correlated with miRNAs (Spearman's correlation test) (n=61).](102746.fig2){#f2-1020746}

Our group recently showed that the frequency of IL-10-competent B cells adversely impacts lymphodepletion following rituximab treatment of CLL patients and also correlates with clinical response assessed 3 months after immunochemotherapy by FCR.^[@b34-1020746]^ Because we reported that the IL-10-competent regulatory B cells frequency predicts efficacy of rituximab-mediated lymphodepletion and clinical CLL outcome, we integrated this third variable in our analysis. Logistic regression analyses showed that only IL-10-competent B cells frequency and miR-532-3p were associated with 90% lymphodepletion after rituximab monotherapy (odds ratio (OR)=0.87; 95% confidence interval (CI)=0.76--0.97; *P*=0.014, and OR=0.0002; 95% CI=\<10-4-0.34; *P*=0.029, respectively). Receiver operating characteristic curve (ROC) using IL-10-competent B cells frequency and miR-532-3p expression levels showed a highly discriminative power (area under the curve (AUC)=0.795; 95% CI=0.652--0.939), allowing one to predict patients who will have more than 90% of lymphodepletion after rituximab pre-phase.

Putative and validated target genes of miR-125b and miR-532-3p
--------------------------------------------------------------

Using the miRWalk database, a tool that compares miRNAs binding sites resulting from 5 main existing miRNA-target prediction programs (DIANA, RNA22, PicTar, miRanda and TargetScan), we investigated putative target genes for the two miRNAs associated with rituximab-induced lymphodepletion.^[@b37-1020746]^ Two lists of putative target genes were obtained: 5053 genes for miR-125b and 6652 for miR-532-3p. The Venny program, an interactive tool for comparing lists, identified 3151 common genes targeted by both miR-125b and miR-532-3p.^[@b38-1020746]^ We then compared them with transcriptomic datasets available for IL-10-competent B cells.^[@b39-1020746]^ Among the 104 genes differentially expressed in the study that compared IL-10^+^ and IL-10^−^ human regulatory B cells, 33 and 46 genes overlapped with miR-125b and miR-532-3p putative targeted genes, respectively.^[@b39-1020746]^ Importantly, 26 genes were common targets of both miRNAs ([Figure 3A](#f3-1020746){ref-type="fig"}). Consequently, in the context of rituximab, which is known to target the pan-B-cell marker CD20/MS4A1, we wondered whether this gene could also be targeted by miR-125b and miR-532-3p. We found that both miRNAs were predicted to target MS4A1.

![Target gene prediction for miR-125b and miR-532-3p. (A) To identify putative miR-125b and miR-532-3p target genes, we used miRWalk software. VENNY, an interactive tool for comparing lists with Venn Diagrams, was used to predict common genes between human regulatory B cells IL-10^+^ and IL-10^−^,^[@b39-1020746]^ and putative miR-125b and miR-532-3p target genes. 26 genes putatively targeted by miR-125b and miR-532-3p, and specifically dysregulated in IL-10^+^ B cells transcriptome analysis are listed. (B) The layout of these 26 putative targets was built in the context of rituximab treatment (*MS4A1* (CD20 gene)) using Ingenuity Pathway Analysis (IPA). 9 genes revealed a central role for the IL-10 pathway.](102746.fig3){#f3-1020746}

Pathway enrichment analysis was performed using the web-based bioinformatics application Ingenuity Pathway Analysis (IPA Ingenuity Systems) based on the *in silico* 26 predicted target genes common to miR-125b, miR-532-3p and differentially regulated in human IL-10^−^/IL-10^+^ regulatory B cells, as well as on MS4A1. A hierarchical layout was built with only miRNA/mRNA interactions displaying high predicted scores and for which the correlation was experimentally observed in humans ([Figure 3B](#f3-1020746){ref-type="fig"}). All the 9 genes presented in this figure were associated with the IL-10 pathway (*EGR3, IL1A, IL10, IL10RA, IRF4, IRF5, MS4A1, TLR7* and *TSC22D3*).

Expression of CD20 family members, miR-125b and miR-532-3p on CLL cells
-----------------------------------------------------------------------

We analyzed the association between miR-125b and miR-532-3p expression levels and the CD20 surface expression on CD19^+^/CD5^+^ CLL cells. In both cases, a significant inverse correlation was observed between CD20 protein and miRNA expression levels ([Figure 4](#f4-1020746){ref-type="fig"}). A high expression level of CD20 at the surface of CLL cells correlated with a low expression level of miR-125b and miR-532-3p (*P*=0.0007 and *P*\<0.0001, respectively). Since miRNAs are negative regulators of gene expression, we monitored the mRNA level of CD20 in the blood of CLL patients. CD20 (MS4A1) mRNA tended to be inversely correlated with both miR-125b and miR-532-3p ([Figure 5A](#f5-1020746){ref-type="fig"}). Interestingly, the expression of two other members of the CD20 family, namely MS4A3 and MS4A7, might also be controlled by miR-125b and miR-532-3p. Indeed, both MS4A3 and MS4A7 mRNAs present putative binding sites for miR-125b and miR-532-3p, not only at the 3′UTR region, but also in the promoter, 5′UTR and coding regions as shown in [Figure 5B](#f5-1020746){ref-type="fig"}. MS4A7 mRNA levels were positively correlated with both miR-125b and miR-532-3p expression levels, whereas MS4A3 mRNA levels were positively correlated with miR-125b expression only. Overall, these results suggest that miR-125b and miR-532-3p might differentially control the expression of the CD20 family members.

![Inverse correlation between miR-125b and miR-532-3p expression levels and circulating CD20 surface antigen expression on CD19^+^ cells in CLL patients blood. CD20 expression levels on CD19^+^ lymphocytes were quantified using flow cytometry. PBMCs were collected and miR-125b (r=−0.37) (A) and miR-532-3p (r=−0.29) (B) were quantified using RT-qPCR. Circulating CD20 antigen was correlated to miRNA expression (Spearman's correlation test) (n=61).](102746.fig4){#f4-1020746}

![miR-125b and miR-532-3p expression levels correlate with the expression of three MS4A family members. (A) Spearman's correlation between miR-125b or miR-532-3p and MS4A mRNA family expression levels in CLL patients blood (n=61). (B) Putative miR-125b and miR-532-3p target binding sites on MS4A family members. CDS: coding DNA sequence; rho: correlation coefficient; UTR: untranslated region.](102746.fig5){#f5-1020746}

Discussion
==========

In the study herein, we investigated whether a blood-based miRNA signature can predict the efficacy of rituximab-mediated lymphodepletion in CLL patients, and provide some clue as to the underlying molecular mechanisms. We showed that miR-125b, miR-193b, miR-652 and miR-532-3p expression levels were inversely correlated with lymphocyte counts in untreated patients, and that miR-125b and miR-532-3p negatively correlated with lymphocyte depletion after rituximab monotherapy. Finally, our data suggest that both miR-125b and miR-532-3p expression levels might provide a link between the expression level of CD20 family members and the efficacy of rituximab-mediated lymphodepletion.

Both miR-125b and miR-532-3p have been previously described in leukemia disorders. Recently, it has been shown that miR-125b was involved in specific subtypes of leukemia, either through IRF4 silencing, genetic deletion or chromosomal translocation as evidenced in B-cell leukemia or myeloid leukemia, respectively.^[@b40-1020746]--[@b42-1020746]^ One of the two genes encoding for the mature form of miR-125b, namely miR-125b-1, maps at 11q24, a chromosomal region that is close to the epicenter of 11q23 deletions found in CLL, and might explain why miR-125b expression is reduced in CLL patients compared to healthy donors.^[@b28-1020746]^ In the study herein, although the number of patients with a del11q was small, no correlation was found with miR-125b expression levels. In a recent study investigating miRNA changes upon B-cell receptor stimulation in distinct subclasses of CLL patients, the expression of miR-532-3p was increased at 48 hours exclusively in CLL patients with stable disease.^[@b6-1020746]^ Like miR-125b, the role and implication of miR-532-3p in CLL are established, especially as it is strongly associated with progression-free survival in CLL.^[@b35-1020746]^

Our data thus identify a novel prognostic relevance for miRNAs, and specifically for miR-125b and miR-532-3p, which are able to predict the efficacy of rituximab-mediated lymphodepletion, independently of the clinical outcome. In the study herein, logistic regression analysis showed that IL-10-competent B cells frequency and miR-532-3p were associated with lymphodepletion after rituximab pre-phase, whereas no correlation was found between miRNAs and the clinical response assessed 3 months after immunochemotherapy by FCR.

Taking advantage of the signatures of these 2 miRNAs for predicting the effect of rituximab, we searched for putative target genes according to these variables. Using available software and databases, we identified 3151 common putative target genes for miR-125b and miR-532-3p, which represent over 62% and 50% of miR-125b and miR532-3p targets, respectively. The lack of sequence homology between miR-125b and miR-532-3p, neither for the seed sequence nor for the entire miRNA mature sequence, does not explain such a surprisingly large number of overlapping putative targets. None of the few common validated target genes reported so far for both miRNAs have been studied together in the same cellular context. *In silico* analyses reveal that these two miRNAs rather target distinct sequences and/or regions of the same gene, suggesting a synergistic effect by collective target regulation by both miRNAs. Among the 104 genes differentially expressed between IL-10^+^ and IL-10^−^ cells,^[@b39-1020746]^ we found over 50% of genes putatively targeted by miR-125b and/or miR-532-3p, among which 26 genes are common for both miRNAs. Pathway enrichment analysis identified 9 genes associated with the IL-10 pathway in the rituximab context. Some of these genes are already validated targets for miR-125b. Rossi *et al.* showed that miR-125b was involved in T-cell differentiation through the silencing of IL-10 receptor α (*IL10RA*). MiR-125b expression in CD4^+^ T cells could contribute to the maintenance of the naive state, while its downregulation is associated with the acquisition of an effector-memory phenotype.^[@b26-1020746]^ MiR-125b inhibits the expression of IRF4 in B lymphocytes, diffuse large B-cell lymphomas and myeloma cell lines, and promotes myeloid and B-cell neoplasm by inducing tumorigenesis in mice hematopoietic progenitor cells.^[@b40-1020746],[@b42-1020746],[@b43-1020746]^ An indirect implication of miR-532-3p on TLR7 gene expression mediated by an upregulation of IL-4 was reported in peripheral blood samples from CLL patients.^[@b44-1020746],[@b45-1020746]^ The dysregulation of miR-532-3p was also evidenced in Binet A stage CLL patients as compared with a normal B-cell subset population.^[@b35-1020746]^ Among the miRNAs tested in relation with clinical data, miR-532-3p is part of a miRNA-based signature strongly associated with progression-free survival.^[@b35-1020746]^

In humans, the *MS4A* gene includes CD20 and 18 other genes.^[@b46-1020746]^ Rituximab is a chimeric type I monoclonal antibody that specifically binds to inter-tetramers of CD20.^[@b29-1020746]^ CD20 could form homo- or heterooligomeric complexes with CD20 family members.^[@b47-1020746]^ Herein, we show that miR-125b and miR-532-3p putatively target other members of the *MS4A* family, including *MS4A1* (coding CD20), *MS4A3* (alias Htm4) and *MS4A7*. MS4A3 is a cell surface signaling molecule involved in the cell cycle of hematopoietic and tumor cells, whereas MS4A7 is expressed in lymphoid tissues.^[@b47-1020746],[@b48-1020746]^ However, their role in the mode of action of rituximab is unexplored. Herein, we showed a significant correlation between miR-125b and miR-532-3p expression levels and three *MS4A* family members in CLL patients; CD20 being negatively correlated and MS4A3 and MS4A7 being positively correlated.^[@b48-1020746],[@b49-1020746]^ Negative regulation of gene expression by miRNAs through translational repression and deadenylation-dependent decay of messengers is widely described. Emerging evidence reveal that miRNAs and their associated multiprotein complexes can directly or indirectly stimulate gene expression.^[@b50-1020746]^ GW182 is an essential component of the repressive miRNA complex that interacts with Ago1/2, leading to mRNA degradation. In conditions of quiescence, the absence of GW182 favors the interaction of FXR1 with Ago1/2 and induces the translation of the targeted mRNA.^[@b50-1020746]^ In the context of CLL, which is a unique malignancy where quiescent B cells accumulate in the peripheral blood, we may hypothesize that miR-125b and miR-532-3p might differently affect the expression of the 3 *MS4A* family members and thus modulate the lymphodepletion outcome upon rituximab treatment. In [Figure 6](#f6-1020746){ref-type="fig"}, we propose a schematic explanation on how miR-125b and miR-532-3p can act in CLL patient cells to modulate rituximab efficacy on lymphodepletion.

![Schematic representation of the potential mechanisms of action of miR-125b and miR-532-3p on the modulation of rituximab activity in CLL cells. In CLL patients displaying low expression levels of miR-125b and miR-532-3p, the MS4A1 mRNA and CD20 surface receptor are upregulated, while the expression of MS4A3 and MS4A7 mRNA are downregulated (MS4A3 and MS4A7 protein expressions were unknown). Consequently, rituximab (RTX) efficacy is optimum for lymphodepletion (Lymphodepletion +++). In contrast, CLL patients with high expression levels of miR-125b and miR-532-3p display low levels of MS4A1 mRNA and CD20 surface receptor, and high levels of MS4A3 and MS4A7 mRNA (MS4A3 and MS4A7 protein expressions were unknown), which might form hetero-oligomers with CD20 and impede optimal lymphodepletion (Lymphodepletion +) by rituximab. Interrogation marks indicate data that were not experimentally confirmed in the present study.](102746.fig6){#f6-1020746}

Overall, our results suggest that miR-125b and miR-532-3p are potential non-invasive biomarkers, detectable in the peripheral blood of CLL patients before treatment, which predict rituximab-mediated lymphodepletion efficacy. These miRNAs might also play a role in the molecular mechanisms involved in the rituximab-mediated mechanism of action, through their implication in the IL-10 pathway, including IL-10-competent B cells, and through the modulation of the *MS4A* family members' expression. Further investigations in an independent cohort are needed to further explore these hypotheses.
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